×
Back to Agenda
S25 : Exploring Exit Strategies and Challenges for dBM Development in Pharmaceutical Drug Development
Session Chair(s)
Yoshihiko Furusawa, MD, PHD
Head of Rare Diseases, Medical Franchise, Japan Medical Office, Takeda Pharmaceutical Company Limited, Japan
Speaker(s)
NORIHIRO KAWABATA
Specialty Clinical Research Dept. Clinical Science Professional, Chugai Pharmaceutical Co., Ltd., Japan
Kazumichi Minato
CEO, Techdoctor, Inc., Japan
Steve Xu, MD, MSC
Medical Director, Northwestern University, United States
Tomoharu DOHI
, Pharmaceuticals and Medical Devices Agency, Japan
Have an account?